Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke (RIMOSTROKE-1)

NCT07913763 is registered in ClinicalTrials.gov with Sinfatin S.L as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07913763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke (RIMOSTROKE-1)
Lead sponsor
Sinfatin S.L
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2028
Enrollment
80 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic stroke

Arms

As registered; 2 arms.

  • Rimonabant 5 mg ExperimentalRimonabant

    Participants randomized to receive rimonabant 5 mg.

  • Placebo Placebo comparatorPlacebo

    Participants randomized to receive matching placebo.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Six-Minute Walk Test (6MWT) Baseline to end of follow-up (day 135)

    The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.

Lead sponsor's other trials

Sinfatin S.L, most recent start first.